Compass Therapeutics, Inc. (CMPX) Stock Analysis

Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’

Wed, September 23, 2026 at 1:44 PM UTC 3 min read

Compass Therapeutics faced a setback as the FDA raised concerns regarding its filing strategy for Tovecimig, prompting H.C. Wainwright to label it as "risky." This development has raised alarms on Wall Street, as it could delay potential market entry and impact the company's valuation. Investors should closely monitor the situation, as regulatory challenges may affect Compass Therapeutics' future growth and stock performance.

Read full article →

Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M

Mon, May 18, 2026 at 4:50 AM UTC 2 min read

Compass Therapeutics (CMPX) reported a net loss of $18.3 million for Q1 2026, reflecting ongoing challenges in its financial performance. This loss may raise concerns among investors about the company's ability to manage expenses and achieve profitability in the near term. As CMPX continues to develop its pipeline, investors will be closely monitoring future earnings reports and strategic initiatives to assess potential recovery and growth opportunities.

Read full article →